More than 300 million people worldwide are affected by osteoporosis. With the advent of an aging world, many middle-aged and older adults have varying degrees of osteoporosis. The incidence is about 40% in postmenopausal women and about 15% in men. Due to the increasingly aging population, osteoporosis and osteoporotic fractures have become major risk factors threatening public health in China. According to a survey released in October 2020, the prevalence of osteoporosis in China was 19.2% in people aged 50 years and older and 32.0% in people aged over 65 years with 10.7% in men and up to 51.6% in women. By the end of 2020, the number of osteoporosis patients in China was over 150 million and it has kept growing.

Global Nucleic Acid Therapeutics CDMO Market to Reach $4,463.7 Million by 2030

The mechanisms of action of osteoporosis medication are divided into three types: inhibition of bone resorption, promotion of bone formation, and dual action of both. The development of clinical application of bisphosphonates in the treatment of osteoporosis began in the 1990s and has undergone three generations of development. The representative drugs of the first generation are etidronate sodium and disodium clodronate; the representative drugs of the second generation are pamidronate sodium and ibandronate sodium; the representative drugs of the third generation are alendronate sodium, risedronate sodium, zoledronic acid and incardronate sodium. At present, these representative drugs have all been marketed in China.

Zoledronic acid was originally developed by Novartis (trade name: ZOMETA^®) and was initially approved for marketing in the United States in 2001 under the trade name of Zometa^® (4mg), mainly for the treatment of excessive calcium in the blood caused by cancer. In 2007, zaoledronic under the trade name of Reclast^® (5mg) was approved by the US and Europe for the treatment of post-menopausal osteoporosis in women. In 2008, Reclast was also indicated for the prevention of hip fractures in women and men. In 2009, Reclast was approved by the FDA for the treatment of osteoporosis and by the EMA of Europe for the treatment of osteoporosis caused by steroid therapy in men and menopausal women.

According to CRI’s market research, 4mg of zoledronic acid injection was marketed by Novartis in China in 2004, while 5mg of zoledronic acid injection for osteoporosis was approved in China in 2009. Subsequently, several companies’ generic zoledronic acid drugs were marketed in China, decreasing Novartis’ share of zoledronic acid market in China.

Global Nucleic Acid Isolation and Purification Market: Focus on Product, End User, Region/Country Data and Competitive Landscape – Analysis and Forecast, 2021-2031

According to CRI’s market research, in 2020, the sales value of zoledronic acid in China declined to approximately CNY 507 million (USD78 million) because of COVID-19, with a CAGR of approximately -3.9% from 2016 to 2020. Since Novartis’ original drug sells at a much higher price than generic drugs, local Chinese company Chia Tai Tianqing Pharmaceutical then ranked the first in terms of sales value and volume in China’s zoledronic acid market in 2020.

CRI expects that from 2021 to 2025, China’s zoledronic acid market will see growth as COVID-19 is effectively controlled in China.

Topics Covered:

• Impact of COVID-19 on China’s Zoledronic Acid Market
• Development Environment of Zoledronic Acid in China
• Sales Volume of Zoledronic Acid in China
• Sales Volume and Value of Zoledronic Acid in China by Region
• Major Zoledronic Acid Manufacturers in China and Their Market Shares
• Sales Price of Zoledronic Acid in China
• Prospects of China’s Zoledronic Acid Market, 2021-2025

The post Research Report on China’s Zoledronic Acid Market, 2021-2025 first appeared on CRI Report.

Currently vaccination is one of the most effective approaches to prevent the spread of infectious diseases as well as one of the most cost-effective health intervention measures. Vaccination is helpful to trim down large amount of treatment expense.

The research object of the report is human vaccine apart from animal vaccine. Five pharmaceutical giants, MSD, Sanofi, Glaxo SmithKline, Pfizer and Novartis, take up significant share of the global market, with sales volume of over 80% globally. Yet in terms of vaccine output, these five giants totally produce less than 20% of the global output, meaning most of the vaccines are produced by manufacturers in the developing world.

There are more than 30 vaccine manufacturing companies in China so far. They are capable of producing over 40 varieties of vaccines to prevent more than 20 infectious diseases. Compared with the international market, vaccine manufacturing companies in China have a larger total number yet a smaller individual scale.

In China, it is used to classifying vaccines into two catalogues: Vaccine I and Vaccine II. Vaccine I refers to those free vaccines provided by the government for the public, including vaccines against major epidemic diseases such as hepatitis B, epidemic meningitis and tetanus. Vaccines in this category are all priced by the government and purchased through bidding. Vaccine II mainly covers vaccines paid by citizens themselves. For Vaccine II, pricing falls into the hand of companies, thus offering a higher profit margin and yet forming a more fiercely competitive market. Some of the commonly used vaccines in the Vaccine II catalogue include Pneumonia Vaccine, Varicella Vaccine, Type B Haemophilus Influenzae Conjugate Vaccine, Influenza Vaccine and Rabies Vaccine. In China, Vaccine I market is dominated by state-owned enterprises. Foreign and private enterprises gain certain advantages in the Vaccine II market.

In 2015, vaccine market size in China had a value of about CNY 21 billion. During the corresponding period, however, the whole pharmaceutical market in China reached a scale of over CNY 2,000 billion. Sales of vaccine industry took up only about 1% of the whole pharmaceutical industry, much lower than the average 3% of the global market. Therefore, China’s vaccine market still has much room for growth. China is a country with the largest population in the world. Every year newly born babies exceed 10 million yet meanwhile aging population is witnessing a trend of rise. As the economy advances, movement of population in China is frequent, which objectively adds to the wider and faster spread of diseases globally. Outbreaks of new epidemic diseases (such as Avian Influenza, Type A H1N1 Influenza) are more frequent.

Thanks to the technology accumulation over the years, some of China’s private enterprises have gained significant breakthroughs in both the technological field and the market of Vaccine II. However, as the majority of them produce their products through copy and imitation, they are in lack of strength in core technology, manufacturing technique, innovation and competence.

In China, as some problems still remain in the supervision and regulation in human vaccine industry, related accidents pop up constantly. This makes some Chinese residents tend to choose imported vaccines. The huge potential of China’s human vaccine industry attracts international giants in vaccine industry to speed up their entry to Chinese market. In 2009 Novartis offered to purchase 85% shares of Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. at USD 125 million. Such a bid was approved in March 2011. In June 2011, Glaxo SmithKline bought 51% shares of Neptunus Interlong held by Neptunus Pharmaceutical at GBP 24 million and set up a joint-venture subsidiary. In September 2011, Glaxo SmithKline signed with three new partners which were Sinopharm Group Co., Ltd., Shanghai Zuellig Pharmaceutical Co., Ltd. and Beijing Keyuan Xinhai Pharmaceutical Co., Ltd. The three distributors were respectively responsible for the distribution business in Northern, Central and Southern China. Through their cold chain logistics systems around the nation, they can provide services for clients in different parts of China.

It is estimated that China’s vaccine market will still grow at a fast speed in the next few years. However as market competition is getting more intensified, some of the incompetent companies will end up in bankruptcy or be acquired and restructured. Market concentration rate will constantly go up.

Currently as vaccination rate in China is relatively low, growth in the industry in the future will be large. As China’s economy develops further, residents’ health awareness and paying capacity will continue to be improved, which will offer greater opportunities and market for the vaccine industry.

Through this report, readers can acquire the following information or even more:

-Status of China Vaccine Industry

-Government Policy of China Vaccine Industry

-Competition Status of China Vaccine Market

-Segmentation of China Vaccine Market

-Major Vaccine Manufacturers in China

-Development Trend of Vaccine Market

The following enterprises and people are proposed to purchase this report:

-Vaccine Manufacturers

-Medical and Anti-epidemic Institutions

-Research Institutions/Investors Concerned about Vaccine Industry

Table of Contents

1 Basic Concept of Human Vaccine

1.1 Definition

1.2 Development Course of Vaccines

1.3 Classification of Vaccines

1.4 Necessity of Vaccination

2 Analysis on the Global Human Vaccine Market, 2011-2015

2.1 Scale and Structure of Global Vaccine Market

2.1.1 Scale of Global Vaccine Market

2.1.2 People Appropriate for Vaccination

2.1.3 Structure of Global Vaccine Market

2.2 Vaccines for Children

2.2.1 Major Varieties

2.2.2 Market Scale of Vaccines for Children

2.3 Adult Vaccines

2.3.1 Major Varieties

2.3.2 Market Scale of Adult Vaccines

3 Development Environment of China Human Vaccine Industry, 2011-2016

3.1 Economic Environment

3.2 Policy Environment

3.2.1 China’s Immunization Program History

3.2.2 Procedure of Immunization Program

3.3 Relevant Legislation and Criterion of China Vaccine Industry

3.3.1 Research and Registration Stage

3.3.2 Production Stage

3.2.3 Circulation Stage

3.3.4 Supporting Policies of Chinese Government to Vaccine Industry

3.5 Analysis on Problems in China Human Vaccine Industry

4 Analysis on the China Human Vaccine Market, 2011-2015

4.1 Classification of Chinese Vaccines

4.2 Scale of China Vaccine Market

4.2.1 Overview

4.2.2 Structure of China Vaccine Market

4.3 Classification of Chinese Vaccines According to Government Regulation Degrees

4.3.1 Vaccine I Market

4.3.2 Vaccine II Market

4.4 Market Analysis on Major Vaccines in China

4.4.1 Bacillus Chalmette-Guerin

4.4.2 Poliomyelitis Vaccine

4.4.3 Measles-Mumps-Rubella Vaccine

4.4.4 Diphtheria and Tetanus (DTP or DTaP) Vaccine

4.4.5 Encephalitis Vaccine

4.4.6 Meningococcus Vaccine

4.4.7 Human Rabies Vaccine

4.4.8 Type B Haemophilus Influenzae Conjugate Vaccine

4.4.9 Influenza Vaccine

4.4.10 Varicella Vaccine

4.4.11 Hepatitis A Vaccine

4.4.12 Pneumococcus Vaccine

4.4.13 Hepatitis B Vaccine

5 China’s Major Vaccine Manufacturers, 2011-2015

5.1 China National Biotec Group

5.1.1 Overview

5.1.2 Beijing Tiantan Biological Products Co., Ltd.

5.1.3 Subordinate Institutions of Biological Products of China National Biotec Group

5.2 Hualan Biological Engineering Co., Ltd.

5.3 Yunnan Walvax Biotechnology Co., Ltd.

5.4 Dalian Hissen Biological Pharmaceutical Co., Ltd.

5.5 Changchun High-Tech Industry Co., Ltd.

5.6 Shenzhen Kangtai Biological Products Co., Ltd.

5.7 Neptunus Interlong Bio-Technique Co., Ltd.

5.8 Liaoning Chengda Biotechnology Co., Ltd.

5.9 ChongQing ZhiFei Biological Products Co., Ltd.

6 Prospect of China Vaccine Industry, 2016-2020

6.1 Prediction on Supply and Demand

6.1.1 Prediction on Production

6.1.2 Prediction on Market Scale

6.2 Prediction on Development Trend

6.2.1 Technology Trend

6.2.2 Market Trend

6.2.3 Competition Trend

Selected Charts

Chart Introduction on Basic Ingredients of Vaccine

Chart Classification of Human Vaccines

Chart Comparison Between Traditional and New Vaccines

Chart Scale of the Global Vaccine Market, 2005-2015

Chart Introduction on Global Major Vaccines

Chart Major Varieties of Global Pneumonia Vaccine

Chart Major Hepatitis Vaccine in Global Market

Chart World’s Major Infectious Diseases Since the 21st Century

Chart Market Scale of China Vaccine Industry, 2011-2015

Chart Lot Release Volume of BCG Vaccine in China, 2011-2015

Chart Market Scale of China’s MMR Vaccine, 2011-2015

Chart Lot Release Volume of Human Rabies Vaccine in China, 2011-2015

Chart Lot Release Volume of Influenza Vaccine in China, 2011-2015

Chart Prediction on Market Scale of China Vaccine Industry, 2016-2020

Chart Immunization Program Procedure for Chinese Children

Chart Circulation of China’s Vaccines

Chart Prediction on Scale of China Vaccine Market, 2016-2020

The post Research Report on China Human Vaccine Industry, 2011-2020 first appeared on CRI Report.